Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread -- Ignore unavailable to you. Want to Upgrade?

To: SirRealist who wrote (49152)	5/30/2001 11:33:34 AM
From: SirRealist	Respond to of 49816

Positive New Laboratory Studies for Nymox Alzheimer's Disease Drug Candidate WEDNESDAY, MAY 30, 2001 9:57 AM - BusinessWire MAYWOOD, N.J., May 30, 2001 (BW HealthWire) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today positive results from the company's recent laboratory studies of its Alzheimer's disease drug candidate, NXD 3702, based on proprietary drug testing methods. The company plans to advance the drug towards clinical trials in the near future. "If these positive results stay on track, we expect to move ahead to the formal regulatory phases very soon," said Dr. Michael Munzar, Medical Director for Nymox. "This is exciting research with vast potential. While we must remain guardedly optimistic, the laboratory results to date are nevertheless very promising." Nymox has two principal programs to develop treatments for Alzheimer's disease, both based on proprietary drug screening platforms. The first program targets spherons, tiny dense balls of protein found in the brains of everyone from age one. Nymox researchers believe that spherons are the source of the senile plaques, the characteristic abnormality found in abundance in the brains of patients with Alzheimer's disease and widely believed to play a pivotal role in the cause and course of the illness. Nymox researchers believe that stopping or inhibiting the transformation of spherons into senile plaques will stop or slow the progress of this illness. They have succeeded in extracting spherons from human brain tissue and developed novel, proprietary drug screening methodologies based on them. Nymox's second drug development program targets a brain protein called neural thread protein (NTP) which is elevated early in Alzheimer's disease. Nymox's AlzheimAlert(TM) detects elevated levels of NTP in the urine of patients with Alzheimer's disease. The results of this unique and accurate urine test can assist a physician faced with the task of diagnosing whether a patient has Alzheimer's disease. Nymox offers the test at a cost of $295 through its clinical reference laboratory in Maywood, New Jersey. Based on evidence linking NTP to the cell loss found in Alzheimer's disease, Nymox has also developed unique drug screening systems to identify other potential drug candidates for the treatment of Alzheimer's disease. These potential drug candidates are aimed to retard the brain cell loss associated with high levels of NTP. Extensive loss of brain cells and accompanying brain shrinkage is a key part of the Alzheimer's disease process. Alzheimer's disease is the leading cause of dementia and the fourth leading cause of death among the elderly. It is a progressive and at present incurable brain disease of the elderly marked by an inexorable decline in mental abilities, including memory and comprehension, and often accompanied by changes in behavior and personality. It currently afflicts an estimated four million people in the United States and at least 15 million people worldwide. As the baby-boomer generation continues to age, these figures are expected to rise sharply. Nymox also has several antibacterials in development, including potential treatments for E. coli 0157 food contamination, and other antibacterials for urinary tract infections and staph and strep infections. The Company's R&D pharmaceutical pipeline also includes candidate drugs for other indications in development. Nymox's second proprietary marketed product, NicAlert(TM), is available in the U.S. and Japan. NicAlert(TM) is an inexpensive, simple-to-use test strip that uses urine or saliva to determine whether a person is using tobacco products. It is currently being used in studies of tobacco use and exposure across the U.S., and as a test to determine whether a person, such as a teenager, student athlete or insurance applicant, is using a tobacco product. Nymox Pharmaceutical Corporation has facilities in Maywood, NJ and Montreal. Its stock is traded on NASDAQ with the symbol NYMX. More information is available at nymox.com. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities. CONTACT: Nymox Pharmaceutical Corporation Dr. Michael Munzar, 1-800-93NYMOX www.nymox.com or Sitrick & Company Lew Phelps, 310/788-2850